Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Dec 5:7:14.
doi: 10.1186/1472-6904-7-14.

Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study

Affiliations
Multicenter Study

Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study

Ingeborg Hartz et al. BMC Clin Pharmacol. .

Abstract

Background: A previous study has shown that variations in threshold and intensity (lipid goal attainment) of statins for primary prevention contribute to regional differences in overall consumption of statins in Norway. Our objective was to explore how differences in prevalences of use, dosing characteristics, choice of statin and continuity of therapy in individual patients adds new information to previous results.

Methods: Data were retrieved from The Norwegian Prescription Database. We included individuals from counties with high, average, and low statin consumption, who had at least one statin prescription dispensed during 2004 (N = 40 143).1-year prevalence, prescribed daily dose (PDD), statin of choice, and continuity of therapy assessed by mean number of tablets per day.

Results: The high-consumption county had higher prevalence of statin use in all age groups. Atorvastatin and simvastatin were dispensed in 79-87% of all statin users, and the proportion was significantly higher in the high-consumption county. The estimated PDDs were higher than the DDDs, up to twice the DDD for atorvastatin. The high-consumption county had the highest PDD for simvastatin (25.9 mg) and atorvastatin (21.9 mg), and more users received tablets in the upper range of available strengths. Continuity of therapy was similar in the three counties.

Conclusion: Although differences in age-distribution seems to be an important source of variation in statin consumption, it cannot account for the total variation between counties in Norway. Variations in prevalences of use, and treatment intensity in terms of PDD and choice of statin also affect the total consumption. The results in this study seems to correspond to previous findings of more frequent statin use in primary prevention, and more statin users achieving lipid goal in the highest consuming county.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sales of statins (ATC group C10AA) in Defined Daily Doses (DDDs) per 1000 inhabitants per day in three Norwegian counties and Norway as a whole, 1996–2004. Wholesale statistics, Norwegian Institute of Public Health [3].
Figure 2
Figure 2
One-year prevalence (%) of use of statins in three Norwegian counties by age and gender. Norwegian Prescription Database 2004. High-c county: abbreviation for high-consumption county.
Figure 3
Figure 3
Proportion of all users according to different statins prescribed in three Norwegian counties 1. Norwegian Prescription Database 2004. High-c county: abbreviation for high-consumption county. 1 Statin substance according to the first prescription dispensed in 2004.
Figure 4
Figure 4
Proportion of statin users according to tablet strength of simvastatin and atorvastatin in three Norwegian counties 1. Norwegian Prescription Database 2004. High-c county: abbreviation for high-consumption county. 1Tablet strength according to the first prescription dispensed in 2004.

Similar articles

Cited by

References

    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1. - DOI - PubMed
    1. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005;60:543–551. doi: 10.1111/j.1365-2125.2005.02478.x. - DOI - PMC - PubMed
    1. Drug sales statistics in Norway. Norwegian Institute of Public Health, Oslo Norway http://www.legemiddelforbruk.no/english
    1. Hartz I, Skurtveit S, Furu K, Njolstad I, Eggen AE. Why do sales of lipid-lowering drugs vary between counties in Norway? Evidence from the OPPHED Health Study 2000–2001. Scand J Prim Health Care. 2006;24:115–121. doi: 10.1080/02813430500475365. - DOI - PubMed
    1. The Norwegian Prescription Registry (NorPD) http://www.fhi.no/eway/default.aspx?pid=238&trg=MainLeft_5853&MainArea_5...

Publication types

MeSH terms